# Effect of a supervised intermittent exercise program on insomnia in breast cancer patients undergoing chemotherapy

**Authors:** Chloé Drozd, Elsa Curtit, Quentin Jacquinot, Pauline Roux, Sophie Paget-Bailly, Valérie Gillet, Nathalie Meneveau, Fabienne Mougin

PMC · DOI: 10.1007/s10549-026-07923-7 · Breast Cancer Research and Treatment · 2026-02-26

## TL;DR

A 12-week supervised exercise program for breast cancer patients undergoing chemotherapy did not increase total sleep time but improved sleep quality and physical fatigue.

## Contribution

This study provides evidence that supervised intermittent aerobic exercise can improve sleep quality and physical adaptation in breast cancer patients with insomnia.

## Key findings

- Total sleep time did not increase after the exercise program, but sleep fragmentation decreased.
- Physical and activity-related fatigue showed clinical improvement in the training group.
- Exercise adaptation parameters, both submaximal and maximal, significantly improved in the training group.

## Abstract

Patients with localized breast cancer receiving adjuvant chemotherapy often experience sleep disturbances, especially insomnia, which significantly impacts quality of life. This study primarily aimed to evaluate the effects of a 12-week exercise program on insomnia, with secondary outcomes on sleep quality, anxiety/depression, fatigue, pain, and exercise adaptation.

In this randomized controlled multicenter trial, 20 women with non-metastatic breast cancer and clinically diagnosed insomnia were assigned to a control or training group. The training group underwent a 12-week supervised intermittent aerobic exercise program during chemotherapy. The primary outcome was objective total sleep time; secondary outcomes included insomnia severity, sleep architecture, sleep quality, anxiety/depression, fatigue, pain, and cardiorespiratory capacity. Assessments were performed before chemotherapy (T-1), at baseline (T0), and post-intervention (T3) using polysomnography, actigraphy, validated questionnaires, and a maximal graded exercise test.

The prevalence of clinical insomnia increased from 47% before diagnosis to 71% at T-1, reaching 100% at T0. Total sleep time did not increase after training (p = 0.97), although sleep fragmentation decreased. Clinical improvement was observed in physical and activity-related fatigue. Finally, both submaximal exercise adaptation parameters (power and VO2/HR) and maximal parameters (power, VO2 peak, VO2/HR) significantly improved.

The training did not increase total sleep time, likely due to insomnia’s multifactorial origin. However, training yielded beneficial effects on objective sleep quality and exercise-induced adaptation. Future research is needed to investigate the various etiologies of insomnia to develop tailored and personalized management approaches.

Clinical Trials Number: NCT04867096

The online version contains supplementary material available at 10.1007/s10549-026-07923-7.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989), insomnia (MONDO:0013600)

## Full-text entities

- **Genes:** ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** Epworth sleepiness (MESH:D000077260), acute insomnia syndrome (MESH:D000208), Fatigue (MESH:D005221), CBT-I (MESH:D007319), mental disorders (MESH:D001523), cancer (MESH:D009369), sleep disruption (MESH:D019958), Anxiety (MESH:D001007), neuroinflammation (MESH:D000090862), PLMI (MESH:D020189), ESS (MESH:C538175), Pain (MESH:D010146), Sleep disorders (MESH:D012893), Sleep Apnea Syndrome (MESH:D012891), cognitive impairment (MESH:D003072), chronic (MESH:D002908), sleep fragmentation (MESH:D012892), Apnea-hypopnea (MESH:D020181), Depression (MESH:D003866), breast cancer (MESH:D001943), personality traits (MESH:D010554), Rapid eye movement (MESH:D020923)
- **Chemicals:** cyclophosphamide (MESH:D003520), trastuzumab (MESH:D000068878), Oxygen (MESH:D010100), epirubicin (MESH:D015251), Epirubicin cyclophosphamide (-), melatonin (MESH:D008550)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** RPE — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_4388)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945910/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945910/full.md

---
Source: https://tomesphere.com/paper/PMC12945910